A Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Fremanezumab (Primary)
- Indications CADASIL; Migraine
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Lack of funding to support the trial.
- 15 Mar 2021 Planned initiation date changed from 1 Jan 2021 to 1 Dec 2021.
- 08 Apr 2020 New trial record